Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

CCCC

C4 Therapeutics Inc

Feb 06 • 04:00PM ET

1.82

+0.11 6.43 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD VRTX MRNA ONC CRSP BNTX INCY EXEL NTLA EDIT

| Held by: VTI VXF IBB SCHA PRFZ IWC FESM DFAS AVSC SCHB

Index	-	P/E	-	EPS (ttm)	-1.67	Insider Own	19.11%	Shs Outstand	96.91M	Perf Week	-4.21%
Market Cap	176.38M	Forward P/E	-	EPS next Y	-1.24	Insider Trans	-0.05%	Shs Float	78.40M	Perf Month	-18.02%
Enterprise Value	45.96M	PEG	-	EPS next Q	-0.29	Inst Own	58.72%	Short Float	9.41%	Perf Quarter	-23.21%
Income	-119.08M	P/S	5.86	EPS this Y	7.51%	Inst Trans	0.81%	Short Ratio	4.60	Perf Half Y	-29.46%
Sales	30.11M	P/B	0.87	EPS next Y	11.91%	ROA	-37.12%	Short Interest	7.38M	Perf YTD	-4.71%
Book/sh	2.08	P/C	0.92	EPS next 5Y	7.18%	ROE	-59.98%	52W High	3.72 -51.08%	Perf Year	-50.14%
Cash/sh	1.98	P/FCF	-	EPS past 3/5Y	5.90% -8.92%	ROIC	-56.80%	52W Low	1.09 67.74%	Perf 3Y	-76.99%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-8.06% 10.72%	Gross Margin	73.64%	Volatility	9.05% 6.79%	Perf 5Y	-95.22%
Dividend TTM	-	EV/Sales	1.53	EPS Y/Y TTM	1.98%	Oper. Margin	-395.42%	ATR (14)	0.14	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.76	Sales Y/Y TTM	-10.57%	Profit Margin	-395.51%	RSI (14)	39.35	Recom	1.12
Dividend Gr. 3/5Y	- -	Current Ratio	5.76	EPS Q/Q	-25.12%	SMA20	-12.08%	Beta	2.95	Target Price	9.86
Payout	-	Debt/Eq	0.40	Sales Q/Q	-26.90%	SMA50	-17.59%	Rel Volume	0.51	Prev Close	1.71
Employees	110	LT Debt/Eq	0.36	Earnings	Nov 06 BMO	SMA200	-14.86%	Avg Volume	1.60M	Price	1.82
IPO	Oct 02, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-8.45% 78.34%	Trades		Volume	825,739	Change	6.43%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-25	Initiated	TD Cowen	Buy
Sep-17-25	Initiated	Barclays	Overweight	$8
Sep-15-25	Upgrade	Stephens	Equal-Weight → Overweight	$6
Sep-04-25	Initiated	Guggenheim	Buy	$8
Dec-19-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$8 → $12
Nov-18-24	Initiated	Stephens	Equal-Weight	$4
Jan-29-24	Upgrade	JP Morgan	Underweight → Neutral	$6
Dec-13-23	Upgrade	Stifel	Hold → Buy	$2 → $12
Feb-24-23	Upgrade	Credit Suisse	Underperform → Neutral	$12 → $10
Feb-24-23	Downgrade	JP Morgan	Neutral → Underweight	$15 → $5
Nov-04-22	Downgrade	JP Morgan	Overweight → Neutral	$22 → $15
Oct-11-22	Initiated	Morgan Stanley	Underweight	$6
Apr-28-22	Initiated	Credit Suisse	Underperform	$10
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral	$46 → $15
Mar-10-22	Initiated	JP Morgan	Overweight	$43
Feb-11-22	Resumed	BMO Capital Markets	Outperform	$57
Feb-10-22	Initiated	Wells Fargo	Equal Weight	$25
Nov-23-21	Initiated	BofA Securities	Buy	$54
Oct-14-21	Initiated	SVB Leerink	Mkt Perform	$20
Sep-30-21	Initiated	Stifel	Hold	$45

Show Previous Ratings

Feb-04-26 07:00AM	C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire) -5.97%
Feb-02-26 08:54PM	C4 Therapeutics, Inc. (CCCC): A Bull Case Theory (Insider Monkey) +6.91%
Jan-26-26 04:01PM	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-14-26 07:00AM	C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways (GlobeNewswire)
Dec-31-25 11:13AM	Is C4 Therapeutics (CCCC) One of the Best Biotech Penny Stocks to Buy According to Analysts? (Insider Monkey)
07:00AM	Loading…
Nov-25-25 07:00AM	C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-06-25 08:25AM	C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-04-25 08:35AM	Amicus Therapeutics (FOLD) Beats Q3 Earnings and Revenue Estimates (Zacks) -8.87%
Oct-17-25 09:00AM	Precision Oncology Approaches Drive $312B Market Transformation (PR Newswire)
Oct-16-25 07:08AM	C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering (GlobeNewswire) +11.71%
Oct-01-25 07:00AM	C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
Sep-22-25 07:41AM	C4s multiple myeloma drug to reach pivotal trials after Phase I victory (Clinical Trials Arena) -17.41%
Sep-20-25 11:00AM	C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting (GlobeNewswire)
Sep-15-25 06:33PM	Why C4 Therapeutics Stock Crushed the Market on Monday (Motley Fool) +34.21%
09:30AM	Loading…
Sep-08-25 09:30AM	Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market (PR Newswire)
Sep-04-25 07:00AM	C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration (GlobeNewswire)
Sep-03-25 07:00AM	C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting (GlobeNewswire)
Aug-12-25 08:00AM	Akamis Bio Announces the Appointment of Andrew Hirsch to the Companys Board of Directors (Business Wire) -7.44%
Aug-07-25 08:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +31.63%
07:00AM	C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-01-25 09:35AM	Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
May-07-25 08:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.38%
07:00AM	C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-29-25 05:15PM	Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Mar-03-25 09:35AM	C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -11.44%
Feb-27-25 09:35AM	C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
08:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-26-25 09:35AM	C4 Therapeutics (CCCC) Loses -23.14% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -5.02%
07:00AM	Loading…
Feb-24-25 07:00AM	C4 Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Jan-14-25 07:00AM	C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology (GlobeNewswire) +6.86%
Jan-08-25 07:00AM	C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-25 09:55AM	Here's Why C4 Therapeutics (CCCC) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Dec-30-24 02:48PM	Why C4 Therapeutics (CCCC) Is One of the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
Dec-08-24 12:30PM	C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader (GlobeNewswire)
Nov-20-24 07:00AM	C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors (GlobeNewswire)
Nov-06-24 07:00AM	C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial (GlobeNewswire)
Nov-05-24 09:00AM	C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at the American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) -5.58%
07:05AM	PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer (Business Wire)
Oct-31-24 08:20AM	C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-28-24 04:01PM	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-15-24 04:01PM	C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. (GlobeNewswire) +7.14% +11.11%
Oct-09-24 07:00AM	C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit (GlobeNewswire)
Sep-30-24 04:01PM	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-13-24 10:00AM	C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Sep-10-24 07:00AM	C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen (GlobeNewswire) +13.79%
Sep-08-24 06:05PM	C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Sep-03-24 07:00AM	C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors (GlobeNewswire)
Aug-29-24 07:00AM	C4 Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-14-24 07:00AM	C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation (GlobeNewswire)
Aug-01-24 08:10AM	C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-17-24 07:13AM	C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock? (Zacks) -7.05%
Jul-16-24 04:01PM	C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024 (GlobeNewswire) +13.71%
Jul-09-24 12:00PM	C4 Therapeutics (CCCC) Upgraded to Buy: Here's Why (Zacks) +12.87%
Jul-08-24 07:00AM	C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day (GlobeNewswire)
Jun-29-24 08:45PM	C4 Therapeutics, Inc. (CCCC): Is This the Best Biotech Penny Stock to Buy Now? (Insider Monkey)
Jun-10-24 07:00AM	C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors (GlobeNewswire)
May-28-24 01:24PM	Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults (PR Newswire)
May-10-24 02:52PM	C4 Therapeutics Inc (CCCC) Q1 2024 Earnings: Navigating Challenges with Strategic Collaborations (GuruFocus.com) -9.41%
May-09-24 10:52AM	Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating (MT Newswires) +5.43%
May-08-24 02:53PM	C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates (MT Newswires) -5.01%
01:54PM	CCCC Stock Earnings: C4 Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:00AM	C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-29-24 04:01PM	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-09-24 07:00AM	C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum (GlobeNewswire)
Apr-08-24 08:00AM	C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-28-24 04:36AM	Here's Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC) (Insider Monkey)
Mar-05-24 04:30PM	C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC Degraders at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-04-24 07:00AM	C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins (GlobeNewswire)
Feb-22-24 08:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +21.38%
07:36AM	C4 Therapeutics Inc (CCCC) Reports Full Year 2023 Financial Results and Business Updates (GuruFocus.com)
07:00AM	C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-15-24 10:19AM	C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store? (Zacks) +8.07%
10:00AM	C4 Therapeutics, Inc. (CCCC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Jan-11-24 11:44AM	C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn (Zacks) -5.97%
Jan-09-24 06:20PM	C4 Therapeutics, Inc. (CCCC)'s Technical Outlook is Bright After Key Golden Cross (Zacks) +6.90% +5.77%
04:01PM	C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines (GlobeNewswire)
Jan-04-24 04:01PM	C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals (GlobeNewswire) +9.69%
07:00AM	C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-03-24 11:10AM	C4 Therapeutics (CCCC) Gains 310% in 3 Months: Here's Why (Zacks) -11.35%
Jan-01-24 09:55AM	Wall Street Analysts See a 197.7% Upside in C4 Therapeutics, Inc. (CCCC): Can the Stock Really Move This High? (Zacks)
Dec-27-23 07:35PM	11 Hot Healthcare Stocks To Buy Now (Insider Monkey) +17.54%
Dec-15-23 09:55AM	Wall Street Analysts Think C4 Therapeutics, Inc. (CCCC) Could Surge 222.95%: Read This Before Placing a Bet (Zacks)
Dec-13-23 12:39PM	C4 Therapeutics (CCCC) Soars on Oncology Deal With Merck (Zacks) +135.47%
Dec-12-23 04:01PM	C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma (GlobeNewswire) +98.31%
10:13AM	Why Is C4 Therapeutics (CCCC) Stock Up 72% Today? (InvestorPlace)
07:00AM	C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs) (GlobeNewswire)
Nov-28-23 07:00AM	C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
Nov-20-23 07:00AM	C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment (GlobeNewswire) -6.63%
Nov-13-23 09:55AM	Here's Why C4 Therapeutics, Inc. (CCCC) Looks Ripe for Bottom Fishing (Zacks)
Nov-01-23 11:03AM	C4 Therapeutics discontinues cancer program, waits for Betta payment (FierceBiotech.com) -11.41%
09:40AM	C4 Therapeutics Inc (CCCC) Reports Q3 2023 Financial Results and Business Highlights (GuruFocus.com)
07:00AM	C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-11-23 07:00AM	C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC Degrader in Development for Multiple Myeloma and Non-Hodgkin's Lymphoma (GlobeNewswire)
Sep-05-23 04:01PM	C4 Therapeutics Announces Chief Financial Officer Succession (GlobeNewswire) -7.29% -10.86%
Aug-28-23 06:30PM	12 Best High Risk Penny Stocks to Buy Now (Insider Monkey)
Aug-08-23 08:40AM	C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Lags Revenue Estimates (Zacks)

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
REYNO LEONARD	Chief Medical Officer	Jan 16 '26	Sale	2.22	10,000	22,200	156,382	Jan 16 04:27 PM
Boyle Scott N	Chief Business Officer	Feb 18 '25	Sale	3.15	669	2,107	107,805	Feb 18 04:55 PM
Boyle Scott N	Chief Business Officer	Feb 14 '25	Sale	3.15	490	1,544	110,842	Feb 18 04:55 PM

ASRT Assertio Holdings Inc daily Stock Chart

Peers: SFM OIS DCTH HRTX PBPB MYE OPI NUS FET TSE

| Held by: VTI VXF BSVO RFLR

Index	-	P/E	-	EPS (ttm)	-4.71	Insider Own	2.61%	Shs Outstand	6.42M	Perf Week	8.15%
Market Cap	81.75M	Forward P/E	-	EPS next Y	-2.57	Insider Trans	-5.08%	Shs Float	6.25M	Perf Month	35.10%
Enterprise Value	33.29M	PEG	-	EPS next Q	-3.12	Inst Own	27.45%	Short Float	4.35%	Perf Quarter	13.21%
Income	-28.92M	P/S	0.60	EPS this Y	-73.70%	Inst Trans	0.40%	Short Ratio	5.22	Perf Half Y	17.30%
Sales	137.35M	P/B	0.77	EPS next Y	57.07%	ROA	-9.71%	Short Interest	0.27M	Perf YTD	40.46%
Book/sh	16.49	P/C	0.87	EPS next 5Y	-	ROE	-24.48%	52W High	15.15 -15.91%	Perf Year	5.53%
Cash/sh	14.56	P/FCF	6.13	EPS past 3/5Y	-96.92% 55.01%	ROIC	-19.22%	52W Low	7.71 65.34%	Perf 3Y	-78.92%
Dividend Est.	-	EV/EBITDA	2.38	Sales past 3/5Y	4.02% -11.45%	Gross Margin	45.68%	Volatility	6.52% 6.34%	Perf 5Y	-69.12%
Dividend TTM	-	EV/Sales	0.24	EPS Y/Y TTM	58.12%	Oper. Margin	-12.29%	ATR (14)	0.70	Perf 10Y	-98.62%
Dividend Ex-Date	-	Quick Ratio	1.43	Sales Y/Y TTM	9.21%	Profit Margin	-21.06%	RSI (14)	65.97	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.58	EPS Q/Q	450.85%	SMA20	11.70%	Beta	0.73	Target Price	37.44
Payout	-	Debt/Eq	0.43	Sales Q/Q	69.36%	SMA50	16.37%	Rel Volume	1.17	Prev Close	11.62
Employees	58	LT Debt/Eq	0.42	Earnings	Nov 10 AMC	SMA200	14.56%	Avg Volume	52.07K	Price	12.74
IPO	Dec 02, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	229.41% 83.05%	Trades		Volume	60,743	Change	9.64%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-26-24	Initiated	Maxim Group	Buy	$3
Jul-03-24	Initiated	H.C. Wainwright	Buy	$4
Nov-07-22	Initiated	Lake Street	Buy	$7
Nov-30-18	Downgrade	Mizuho	Buy → Neutral

Feb-06-26 11:31AM	KOD Stock Up 24% in 3 Months: Here's What You Need to Know (Zacks) +9.64%
Feb-05-26 11:42AM	Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results (Zacks)
Feb-04-26 10:11AM	FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway (Zacks)
Feb-03-26 11:59AM	Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study (Zacks)
06:28AM	Strength Seen in Harrow (HROW): Can Its 9.7% Jump Turn into More Strength? (Zacks)
11:03AM	Loading…
Feb-02-26 11:03AM	Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome (Zacks)
09:55AM	Wall Street Analysts See a 230.56% Upside in Assertio (ASRT): Can the Stock Really Move This High? (Zacks)
Jan-30-26 10:24AM	FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug (Zacks)
09:40AM	Has ADC Therapeutics (ADCT) Outpaced Other Medical Stocks This Year? (Zacks)
Jan-16-26 09:55AM	Wall Street Analysts Think Assertio (ASRT) Could Surge 249.87%: Read This Before Placing a Bet (Zacks)
Jan-14-26 09:40AM	Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jan-12-26 04:15PM	Assertio Holdings, Inc. Regains Compliance With Nasdaq Listing Requirements (Business Wire) +10.89%
Jan-09-26 01:45PM	Assertio Announces Publication of Rolvedon Same-Day Dosing Clinical Trial (Business Wire)
Dec-22-25 04:30PM	Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split (Business Wire) -9.81%
Nov-11-25 04:01AM	Assertio Holdings Inc (ASRT) Q3 2025 Earnings Call Highlights: Impressive Growth Amid Market ... (GuruFocus.com) +14.89%
05:45PM	Loading…
Nov-10-25 05:45PM	Assertio (ASRT) Surpasses Q3 Earnings and Revenue Estimates (Zacks) +5.33%
04:41PM	Assertio: Q3 Earnings Snapshot (Associated Press Finance)
04:13PM	Assertio Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-06-25 08:30AM	Xeris Biopharma (XERS) Reports Break-Even Earnings for Q3 (Zacks)
Oct-28-25 09:15AM	Assertio Announces Leadership Transition (GlobeNewswire)
Sep-23-25 05:04AM	New Strong Sell Stocks for September 23rd (Zacks)
Sep-19-25 06:23AM	New Strong Sell Stocks for September 19th (Zacks) -7.22%
Sep-16-25 04:59AM	New Strong Sell Stocks for September 16th (Zacks)
Sep-15-25 09:00AM	Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN (clobazam) Oral Film, CIV (GlobeNewswire)
Sep-10-25 07:30AM	Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN at upcoming 150th Annual Meeting of the American Neurological Association (GlobeNewswire)
Sep-03-25 08:15AM	Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025 (GlobeNewswire)
Aug-26-25 06:17AM	New Strong Sell Stocks for August 26th (Zacks)
Aug-12-25 03:06AM	Assertio Holdings Inc (ASRT) Q2 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com) +13.85%
Aug-11-25 06:55PM	Assertio (ASRT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
05:54PM	Assertio: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Assertio Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-08-25 09:31AM	Assertio Holdings Inc (ASRT) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-06-25 03:41PM	Berger Montague PC Investigating Claims on Behalf of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors (PR Newswire)
08:30AM	NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-05-25 08:30AM	Assertio Holdings, Inc. to Report Second Quarter 2025 Financial Results on August 11, 2025 (GlobeNewswire)
Jul-08-25 06:28AM	New Strong Sell Stocks for July 8th (Zacks)
Jun-30-25 06:03AM	New Strong Sell Stocks for June 30th (Zacks)
Jun-25-25 06:26AM	New Strong Sell Stocks for June 25th (Zacks)
Jun-18-25 05:08AM	New Strong Sell Stocks for June 18th (Zacks)
May-19-25 04:10PM	Assertio to Participate in the Alliance Global Partners Healthcare Company Showcase on May 21, 2025 (GlobeNewswire) +6.77%
May-13-25 05:38AM	Q1 2025 Assertio Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Assertio Holdings Inc (ASRT) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
May-12-25 05:15PM	Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:20PM	Assertio: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Assertio Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-09-25 09:48AM	Assertio Holdings Inc (ASRT) Q1 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
May-08-25 05:40PM	OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-05-25 08:15AM	Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025 (GlobeNewswire) -6.46%
Apr-07-25 09:17AM	Journey Medical (DERM) Surges 9.1%: Is This an Indication of Further Gains? (Zacks) -6.19%
Mar-21-25 09:00AM	iAccess Alpha's Virtual Best Ideas Spring Investment Conference March 25-26, 2025 (ACCESSWIRE)
Mar-20-25 09:10AM	Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025 (GlobeNewswire)
Mar-13-25 12:58PM	Q4 2024 Assertio Holdings Inc Earnings Call (Thomson Reuters StreetEvents) -7.46%
03:08AM	Assertio Holdings Inc (ASRT) Q4 2024 Earnings Call Highlights: Strategic Growth Amidst Challenges (GuruFocus.com)
Mar-12-25 04:30PM	Assertio: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Assertio Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-05-25 04:05PM	Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025 (GlobeNewswire) +6.49%
Jan-03-25 04:30PM	Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-17-24 08:30AM	Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors (GlobeNewswire)
Dec-13-24 08:00AM	Assertio Announces Results of Rolvedon (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study (GlobeNewswire)
Dec-12-24 08:00AM	Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO (GlobeNewswire)
Dec-06-24 07:00AM	Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer (GlobeNewswire)
Nov-15-24 09:00AM	Buxton Helmsley Calls for Senate Hearing on Well-Documented Evident Clinical Data Fraud at Assertio (Business Wire)
Nov-12-24 09:41AM	Q3 2024 Assertio Holdings Inc Earnings Call (Thomson Reuters StreetEvents) -7.89%
Nov-11-24 04:09PM	Assertio: Q3 Earnings Snapshot (Associated Press Finance) +8.82%
04:02PM	Assertio Reports Third Quarter 2024 Financial Results (GlobeNewswire)
03:41PM	Buxton Helmsley Releases Evidence of Product-Related Fraud at Assertio (Business Wire)
07:30AM	Assertio Provides Response to Letter from Short-seller (GlobeNewswire)
Nov-08-24 09:00AM	Buxton Helmsley Issues Letter to Assertio Stockholders Disclosing Inversion to Short Position Following Board Refusal to Address Product-Related Fraud (Business Wire) -15.84%
07:06AM	Assertio Holdings Inc (ASRT) Q3 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
Oct-30-24 08:00AM	Assertio Holdings, Inc. to Report Third Quarter 2024 Financial Results on November 11, 2024 (GlobeNewswire)
Oct-11-24 08:00AM	Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024 (GlobeNewswire)
Oct-09-24 05:18PM	Assertio Holdings Inc (ASRT) Q2 2024 Earnings Call Highlights: Navigating Sales Challenges and ... (GuruFocus.com)
Oct-04-24 04:05PM	Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-24 04:05PM	Assertio to Participate in the HC Wainwright and Lake Street Conferences in New York City September 10-12, 2024 (GlobeNewswire) -5.93% +10.81%
Aug-07-24 04:47PM	Assertio: Q2 Earnings Snapshot (Associated Press Finance) -11.79%
04:01PM	Assertio Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-24-24 04:05PM	Assertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024 (GlobeNewswire) -6.17%
09:00AM	Buxton Helmsley Issues Letter to the Board of Directors of Assertio Holdings, Inc. (Business Wire)
Jul-09-24 04:30PM	Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +8.11%
Jun-11-24 10:50AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
Jun-06-24 04:05PM	Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-05-24 08:30AM	Assertio to Participate in the Sidoti Small Cap Conference on June 12, 2024 (GlobeNewswire)
May-29-24 07:00AM	Assertio Announces the Appointment of Brendan P. O'Grady as New CEO (GlobeNewswire)
May-17-24 09:15AM	Assertio to Participate in Benchmark Healthcare Conference on May 21-22 (GlobeNewswire)
07:30AM	BUXTON HELMSLEY RELEASES LETTER FROM CERTIFIED FRAUD EXAMINER ATTESTING TO DISCLOSURE FAILURES AND DEFICIENCIES BY ASSERTIO HOLDINGS BOARD OF DIRECTORS (PR Newswire)
May-16-24 09:16AM	Assertio to Participate in AGP Healthcare Conference on May 21 (GlobeNewswire)
May-13-24 05:52PM	BUXTON HELMSLEY URGES ASSERTIO STOCKHOLDERS TO VOTE 'AGAINST' DIRECTORS AFTER DISCLOSURE FAILURES, INAPPROPRIATE BOARDROOM ACTIVITY, STRATEGIC BLUNDERS (PR Newswire) +9.38%
May-10-24 03:12PM	Assertio to Present at the Citizens JMP Life Sciences Conference in New York City (GlobeNewswire) -8.57%
May-07-24 10:28AM	Assertio Holdings, Inc. (NASDAQ:ASRT) Q1 2024 Earnings Call Transcript (Insider Monkey) -9.02%
05:35AM	Q1 2024 Assertio Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
03:10AM	Assertio Holdings Inc (ASRT) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of ... (GuruFocus.com)
May-06-24 08:59PM	ASRT Stock Earnings: Assertio Holdings Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +18.45%
05:46PM	Assertio Holdings Inc (ASRT) Surpasses Revenue Estimates But Reports Wider Loss in Q1 2024 (GuruFocus.com)
04:21PM	Assertio: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Assertio Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 08:00AM	Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 (GlobeNewswire) -9.30%
Apr-03-24 08:00AM	Sig Kirk Joins Assertio Board of Directors (GlobeNewswire)
Apr-01-24 09:00AM	Assertio to Present at LD Micro Invitational Conference in New York City (GlobeNewswire)
Mar-12-24 11:11AM	Assertio Holdings Inc (ASRT) Reports Mixed Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com) +8.06%
08:31AM	Assertio Holdings, Inc. (NASDAQ:ASRT) Q4 2023 Earnings Call Transcript (Insider Monkey)

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stark David Matthew	Director	Nov 10 '25	Sale	0.76	8,959	6,806	98,541	Nov 12 06:00 PM
DAVID STARK	Director	Nov 10 '25	Proposed Sale	0.76	8,959	6,806		Nov 10 04:07 PM
O'Grady Brendan P.	CEO	May 31 '25	Option Exercise	0.00	166,665	0	178,371	Jun 03 06:00 PM
Schlessinger Sam	EVP, General Counsel	May 12 '25	Option Exercise	0.00	38,017	0	191,906	May 14 06:03 PM
Schwichtenberg Paul	See Remarks	May 12 '25	Option Exercise	0.00	38,017	0	184,362	May 14 06:01 PM
Patel Ajay	EVP and CFO	May 12 '25	Option Exercise	0.00	38,017	0	213,692	May 14 06:00 PM
Schlessinger Sam	SVP, General Counsel	Feb 21 '25	Option Exercise	0.00	17,150	0	161,545	Feb 25 06:03 PM
Schwichtenberg Paul	See Remarks	Feb 21 '25	Option Exercise	0.00	17,150	0	154,850	Feb 25 06:02 PM
Patel Ajay	SVP and CFO	Feb 21 '25	Option Exercise	0.00	17,150	0	184,180	Feb 25 06:00 PM

CCCC

C4 Therapeutics Inc

ASRT

Assertio Holdings Inc

Upgrade your FINVIZ experience